PerkinElmer, Inc. (PKI): Price and Financial Metrics


PerkinElmer, Inc. (PKI)

Today's Latest Price: $148.52 USD

0.39 (0.26%)

Updated Jan 15 7:00pm

Add PKI to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 185 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

PKI Stock Summary

  • PKI has a higher market value than 87.34% of US stocks; more precisely, its current market capitalization is $16,586,780,463.
  • PKI's went public 35.06 years ago, making it older than 92.8% of listed US stocks we're tracking.
  • Over the past twelve months, PKI has reported earnings growth of 78.73%, putting it ahead of 85.87% of US stocks in our set.
  • Stocks that are quantitatively similar to PKI, based on their financial statements, market capitalization, and price volatility, are GNRC, TFX, XYL, WAB, and FTV.
  • PKI's SEC filings can be seen here. And to visit Perkinelmer Inc's official web site, go to www.perkinelmer.com.

PKI Stock Price Chart Interactive Chart >

Price chart for PKI

PKI Price/Volume Stats

Current price $148.52 52-week high $162.70
Prev. close $148.13 52-week low $62.91
Day low $146.03 Volume 824,800
Day high $149.49 Avg. volume 1,138,390
50-day MA $140.38 Dividend yield 0.19%
200-day MA $115.47 Market Cap 16.63B

PerkinElmer, Inc. (PKI) Company Bio


PerkinElmer Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, and laboratory services markets worldwide. The company operates through two segments, Human Health and Environmental Health. The company was founded in 1931 and is based in Waltham, Massachusetts.

PKI Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$148.52$79.84 -46%

We started the process of determining a valid price forecast for Perkinelmer Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Perkinelmer Inc ranked in the 37th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for PKI, they are:

  • Interest coverage, a measure of earnings relative to interest payments, is 5.62 -- which is good for besting 56.24% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • 89% of the company's capital comes from equity, which is greater than 71.18% of stocks in our cash flow based forecasting set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-47%
1%-47%
2%-46%
3%-46%
4%-45%
5%-45%

Want more companies with a valuation profile/forecast similar to that of Perkinelmer Inc? See CRL, MGLN, MMSI, IART, and ITGR.


PKI Latest News Stream


Event/Time News Detail
Loading, please wait...

PKI Latest Social Stream


Loading social stream, please wait...

View Full PKI Social Stream

Latest PKI News From Around the Web

Below are the latest news stories about Perkinelmer Inc that investors may wish to consider to help them evaluate PKI as an investment opportunity.

Masimo (MASI) Reports Encouraging 2020 Preliminary Results

Per the preliminary announcement, Masimo (MASI) projects 2020 product revenues to improve.

Yahoo | January 15, 2021

PerkinElmer nabs FDA EUA nod for COVID-19 kit for asymptomatic testing

PerkinElmer ([[PKI]] +0.3%) said its New Coronavirus Nucleic Acid Detection Kit received Emergency Use Authorization ((EUA)) from the FDA to test individuals without symptoms or other reasons to suspect COVID-19 infection.Previously, the FDA issued EUA to allow sample pooling with PKI's New Coronavirus Nucleic Acid Detection Kit to increase the number of individuals...

Seeking Alpha | January 14, 2021

Top Ranked Growth Stocks to Buy for January 14th

Top Ranked Growth Stocks to Buy for January 14th

Yahoo | January 14, 2021

BD (BDX) Posts Upbeat Preliminary Fiscal First Quarter Results

BD (BDX) projects its fiscal Q1 revenues to surge from the year-ago figure, primarily on the back of high demand for its COVID-19 diagnostic tests

Yahoo | January 14, 2021

PerkinElmer SARS-CoV-2 RT-PCR Assay Receives FDA EUA for Asymptomatic Testing

PerkinElmer, Inc. (NYSE:PKI) announced today that its PerkinElmer® New Coronavirus Nucleic Acid Detection Kit received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to test individuals without symptoms or other reasons to suspect COVID-19 infection.

Yahoo | January 14, 2021

Read More 'PKI' Stories Here

PKI Price Returns

1-mo 4.08%
3-mo 20.38%
6-mo 32.65%
1-year N/A
3-year 85.26%
5-year 218.53%
YTD 3.50%
2020 48.20%
2019 24.01%
2018 7.80%
2017 40.99%
2016 -2.12%

PKI Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full PKI Dividend History

Continue Researching PKI

Want to see what other sources are saying about Perkinelmer Inc's financials and stock price? Try the links below:

Perkinelmer Inc (PKI) Stock Price | Nasdaq
Perkinelmer Inc (PKI) Stock Quote, History and News - Yahoo Finance
Perkinelmer Inc (PKI) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.955 seconds.